Key result
ECE-2 localizes to cytosolic secretory vesicles in human vascular endothelial cells.
This study provides the first immunocytochemical and biochemical evidence for the presence and intracellular localization of ECE-2 in human vascular endothelial cells.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications; leaves open ECE-2 as a target for vascular endothelin research.
We have previously reported the intracellular localization of the endothelin-converting enzyme-1 (ECE-1) in human umbilical vein endothelial cells. In the present study, we provide the first immunocytochemical and biochemical evidence for the presence of ECE-2 in human cells. ECE activity was determined by conversion of exogenously added big endothelin-1 (big ET-1) to ET-1 in subcellular fractions obtained by sucrose density gradient centrifugation of human umbilical vein endothelial cell homogenates. ECE-1 and ECE-2 can be differentiated by pH dependence for optimal activity and by sensitivity to phosphoramidon, which shows selectivity for ECE-2 over ECE-1 and PD159790, a novel ECE-1 selective inhibitor. Optimal ECE activity was measured at pH 6.0, a value intermediate between that reported for ECE-1 (pH 6.8) and ECE-2 (pH 5.5), indicating expression of both enzymes. At pH 6.9, conversion of big ET-1 was inhibited markedly by 30 micromol/L PD159790 and by 100 micromol/L phosphoramidon but not by 0.1 micromol/L phosphoramidon. In contrast, ECE activity was unaffected by 30 micromol/L PD159790 but was inhibited markedly by 0.1 and 100 micromol/L phosphoramidon at pH 5. 4 (IC50 1.5 nmol/L), consistent with ECE-2 activity. Confocal microscopy revealed a punctate pattern of ECE-2-like immunoreactive staining in the cell cytosol, suggesting localization to secretory vesicles with a possible role in processing big ET-1 while in transit to the cell surface via the constitutive secretory pathway.
No takes yet. Share an insight, caveat, or question.
Russell et al. (1999) studied this question. ECE inhibitors (PD159790 and phosphoramidon) was evaluated on ECE activity (conversion of big ET-1 to ET-1). Immunocytochemical and biochemical evidence demonstrates the presence of ECE-2 in human vascular endothelial cells, localized to secretory vesicles in the cytosol.
Synapse has enriched 10 related papers. Consider them for comparative context: